General Information About HIV Medications
- HIV Drug Chart. Chart from Positively Aware’s Drug Guide with basic information about each antiretroviral drug and combination pill or tablet approved by FDA. For each drug or combination, the chart includes: its brand name, generic name, and common abbreviations used; detailed dosing information; and a color image.
- Treatments for HIV and AIDS. Web page from Poz that lists FDA-approved antiretroviral drugs (ARVs), as well as selected experimental drugs. For each drug or combination, the page includes: a small color picture of the pill or tablet, its brand name, generic name, and common abbreviations; and a link to an associated web page with more detailed information about drug, including what it is, how it is dosed, and drug interactions and side effects.
- FDA-Approved HIV Medicines (AIDSinfo) This page has a list of medications used to treat HIV infection, including generic and brand names and date approved by the Food and Drug Administration for use in the United States. For each drug, there is a link to an associated fact sheet with information about that specific medication. Also available in Spanish.
Fact Sheets About Nucleoside and Nucleotide Analogues (Nukes)
- Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) (Poz)
- Zidovudine (Retrovir) (AIDS InfoNet) and Spanish version
- Retrovir (Poz)
- Zalcitabine (HIVid, ddC) (AIDS InfoNet) and Spanish version
- Didanosine (Videx) (AIDS InfoNet) and Spanish version
- Videx EC (Poz)
- Stavudine (Zerit, d4T) (AIDS InfoNet) and Spanish version
- Zerit (Poz)
- Lamivudine (Epivir) (AIDS InfoNet) and Spanish version
- Epivir (Poz)
- Abacavir (Ziagen) (AIDS InfoNet) and Spanish version
- Ziagen (Poz)
- Tenofovir (Viread) (AIDS InfoNet) and Spanish version
- Viread (Poz)
- Emtricitabine (Emtriva) (AIDS InfoNet) and Spanish version
- Emtriva (Poz)
Fact Sheets About Pills Combining More Than One Drug, Including at Least One Nuke
- Combination Medications (AIDS InfoNet) and Spanish version
- Combivir (zidovudine + lamivudine) (AIDS InfoNet) and Spanish version
- Combivir (Poz)
- Trizivir (zidovudine + lamivudine + abacavir) (AIDS InfoNet) and Spanish version
- Trizivir (Poz)
- Epzicom/Kivexa (abacavir + lamivudine) (AIDS InfoNet) and Spanish version
- Epzicom (Poz)
- Truvada (tenofovir + emtricitabine) (AIDS InfoNet) and Spanish version
- Truvada (Poz)
- Atripla (efavirenz + emtricitabine + tenofovir) (AIDS InfoNet) and Spanish version
- Atripla (Poz)
- Complera/Eviplera (rilpivirine + emtricitabine + tenofovir) (AIDS InfoNet) and Spanish version
- Complera (Poz)
- Stribild (elvitegravir + cobicistat + emtricitabine + tenofovir) (AIDS InfoNet) and Spanish version
- Stribild (Poz)
- Triumeq (dolutegravir + abacavir + lamivudine) (AIDS InfoNet) and Spanish version
- Triumeq (Poz)
- Genvoya (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate) (AIDSInfo) and Spanish version
- Genvoya (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) (AIDS InfoNet)
- Odefsey (Emtricitabine/Rilpivirine/Tenofovir Alafenamide (AIDSInfo) and Spanish version
- Odefsey (rilpivirine + emtricitabine + tenofovir alafenamide) (Poz)
- Descovy (Poz)
- Descovy (tenofovir alafenamide + emtricitabine) (AIDS InfoNet)
Articles About Experimental or Recently Approved Nukes
- Tenofovir Levels in Blood 4-Fold Higher With TAF Than TDF. (July 2016, TheBodyPro)
- Studies examine switch to TAF-based regimens in patients with renal impairment. (July 2016, Healio)
- Switching to TAF Noninferior to Continuing TDF in Double-Blind Trial. (June 2016, TheBodyPro)
- Descovy, New HIV Drug Containing Tenofovir Alafenamide, Approved by FDA. (April 2016, TheBodyPRO); related coverage from Beta Blog, Healio, and Poz
- Long-acting oral antiretroviral MK-8591 could represent ‘paradigm shift’ in HIV treatment and prophylaxis. (April 2016, AIDSmap)
- Switching to regimen with new form of tenofovir (TAF) improves kidney and bone health markers. (April 2016, Project Inform)
- New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP. (March 2016, HIV Treatment Bulletin)
- New single tablet regimen Odefsey approved for treating HIV infection. (March 2016, Project Inform); related coverage from Beta Blog, Healio, and Poz
- New HIV treatments discussed at CROI 2016. (March 2016, Beta Blog)
- Tenofovir twin continues to perform well. (February 2016, MedPage Today)
- Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety. (October 2015, AIDSmap)
- Studies continued to support tenofovir alafenamide combination pill as it nears US approval. (October 2015, AIDSmap)
- ICAAC 2015: Stribild Superior for Women; Better Safety & Efficacy of TAF. (October 2015, Beta Blog)
- New antiretrovirals and HIV treatment strategies highlighted at ICAAC. (October 2015, AIDSmap)
- Five Promising HIV Drugs in the Pipeline. (September 2015, TheBodyPro)
- People with HIV and hepatitis B co-infection can safely switch to simpler TAF single-tablet regimen. (August 2015, AIDSmap)
- Tenofovir Alafenamide (TAF) Still Noninferior to Current Tenofovir – With Better Bone/Kidney Signals. (August 2015, TheBodyPro)
- New Antiretrovirals, New Formulations, and New Strategies for HIV Treatment. (August 2015, Beta Blog)
- Updated Tenofovir Is Safer for Bones and Kidneys. (July 2015, Poz)
- New and Improved Tenofovir Combination Submitted for FDA Approval. (April 2015, TheBodyPro)
- An “Improved Backbone” for New HIV Regimens Now Under FDA Review. (April 2015, Beta Blog)
- It’s Time for Tenofovir 2.0. (December 2014, Poz)
- FDA Reviews First Single-Tablet HIV Regimen Containing TAF. (November 2014, Poz)
- BMS-986001 Bone, Metabolic Data Compare Well to Tenofovir Through 48 Weeks. (October 2014, TheBodyPro)
- New HIV Drug, BMS-986001, Safe and Effective in Treatment-Naive Patients. (September 2014, TheBodyPro)
- CROI Report: New Drugs for HIV Treatment and other random thoughts. (March 2013, NATAP)
- New pro-drug tenofovir alafenamide appears equally effective but better tolerated. (March 2013, AIDSmap)
- New Tenofovir Prodrug Shows Potency, Plus Better Kidney and Bone Safety Than Current Formulation. (March 2013, TheBodyPro)
- Gilead Begins Phase III Studies of Low-Dose Prodrug Tenofovir Alafenamide. (January 2013, Poz)